Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2020
Where the money goes
Where each dollar of revenue went, fiscal 2020
- Research and development60¢$65.4M
- Selling, general and admin40¢$43.2M
- Interest0¢$21.0K
- Income tax0¢$182.0K
Out of $8.3M in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
| Fiscal year | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $95.0M4 | $35.7M5 | $26.1M6 | $12.3M6 | $1.4M7 | $5.1M3 | $8.3M3 |
| Cost of revenue | $3.9M6 | $3.0M6 | $682.0K6 | ||||
| Gross profit | $84.0M4 | $29.7M5 | $22.2M6 | $9.3M6 | $714.0K7 | $3.8M3 | $6.3M3 |
| Research and development | $32.9M4 | $33.6M5 | $35.8M6 | $40.8M6 | $49.0M7 | $56.5M3 | $65.4M3 |
| Selling, general and admin | $89.3M4 | $104.7M5 | $105.9M6 | $37.1M6 | $37.6M7 | $36.4M3 | $43.2M3 |
| Operating income | -$38.3M4 | -$139.9M5 | -$115.4M6 | -$68.6M6 | -$85.9M7 | -$89.1M3 | -$102.3M3 |
| Interest | $28.9M4 | $27.2M5 | $72.6M6 | $6.0M6 | $4.6M7 | $3.4M3 | $21.0K3 |
| Income tax | -$29.0K4 | -$3.0K5 | $342.0K6 | -$121.0K6 | -$524.0K7 | $46.0K3 | -$182.0K3 |
| Net income | -$64.4M4 | -$147.1M5 | -$208.8M6 | -$79.8M6 | -$54.3M7 | -$61.4M3 | -$108.9M3 |
No quarterly figures reported.
| Fiscal year | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | $21.0M5 | $21.5M5 | $36.1M6 | $67.5M6 | $94.7M7 | $139.6M3 | $74.4M3 |
| Current assets | $32.7M4 | $40.3M5 | $70.0M6 | $98.9M7 | $184.6M3 | $137.3M3 | |
| Total assets | $84.1M4 | $62.6M5 | $83.6M6 | $144.7M7 | $214.8M3 | $162.7M3 | |
| Current liabilities | $49.7M4 | $24.7M5 | $56.6M6 | $24.0M7 | $28.7M3 | $29.5M3 | |
| Long-term debt | $209.7M4 | $28.7M5 | $33.7M6 | $27.5M6 | |||
| Total liabilities | $296.2M4 | $87.7M5 | $81.8M6 | $56.2M7 | $49.1M3 | $46.7M3 | |
| Shareholders’ equity | -$155.4M5 | -$270.9M6 | -$25.2M6 | $1.8M6 | $88.4M7 | $165.7M3 | $116.0M3 |
| Shares outstanding | 0 shares4 | 45.1M shares5 | 78.6M shares6 | 113.1M shares7 | 159.8M shares3 | 171.5M shares3 |
Corporate structure
Kadmon Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Kadmon Holdings, Inc.
- Point72 Asset Management, L.P. Filed SC 13G/A on Kadmon Holdings, Inc., latest Feb 14, 2022
- Kadmon Holdings, Inc. New York, New York
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Kadmon Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $300.0K7 Dec 31, 2019 | $700.0K7 Dec 31, 2018 | −57.1% |
| Property and equipment, before depreciation | $19.7M3 Dec 31, 2020 | $19.2M3 Dec 31, 2019 | +2.5% |
| Accumulated depreciation | $18.4M3 Dec 31, 2020 | $16.8M3 Dec 31, 2019 | +9.8% |
| Property and equipment, net | $1.3M3 Dec 31, 2020 | $2.4M3 Dec 31, 2019 | −47.3% |
| Operating-lease assets (leased space) | $16.1M3 Dec 31, 2020 | $19.7M3 Dec 31, 2019 | −18.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $74.4M3 Dec 31, 2020 | $139.6M3 Dec 31, 2019 | −46.7% |
| Marketable securities, current | $49.4M3 Dec 31, 2020 | ||
| Debt securities available for sale | $123.9M3 Dec 31, 2020 | $139.6M3 Dec 31, 2019 | −11.3% |
| Equity securities at fair value | $10.6M3 Dec 31, 2020 | $42.0M3 Dec 31, 2019 | −74.8% |
Intangibles and goodwill
Inventory
Leadership
Who has led Kadmon Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerHarlan Waksal Jul 26, 2016 to Nov 9, 20218
- PresidentHarlan Waksal Jul 26, 2016 to Nov 9, 20218
- Chief financial officerSteven Meehan Feb 11, 2019 to Nov 9, 20219
- Chief financial officerKonstantin Poukalov Jul 26, 2016 to Dec 12, 201710
Board members and other officers (20)
- Principal Accounting OfficerKyle Carver Oct 29, 2018 to Nov 9, 202111
- Principle Accounting OfficerCharles Darder Jul 26, 2016 to Dec 12, 201712
- exec VP, Chief Commercial OffiEva Heyman Jul 26, 2016 to Jul 26, 201613
- Exec. VP, Research & Develop.Larry Witte Jul 26, 2016 to Jul 26, 201614
- Exec. VP, Business Develop.Lawrence Kenneth Cohen Jul 26, 2016 to Dec 16, 201615
- Exec VP, GC, Chief Admin, CompSteven N. Gordon Jul 26, 2016 to Jun 14, 201916
- Executive VP BiologicsZhenping Zhu Jul 26, 2016 to Jul 26, 201617
- Board memberNancy Miller-Rich Aug 13, 2020 to Nov 9, 202118
- Board memberCynthia Schwalm Jan 23, 2019 to Nov 9, 202119
- Board memberDavid E. Cohen Feb 7, 2019 to Nov 9, 202120
- Board memberArthur S. Kirsch May 16, 2019 to Nov 9, 202121
- Board memberSteven Meehan Jan 26, 2017 to Jul 30, 201822
- Board memberTasos Konidaris Feb 17, 2017 to Nov 9, 202123
- Board memberAlexandria Forbes Jul 26, 2016 to Jun 30, 201724
- Board memberBart M. Schwartz Jul 26, 2016 to Jul 30, 201825
- Board memberD. Dixon Boardman Jul 26, 2016 to May 16, 201926
- Board memberHarlan Waksal Jul 26, 2016 to Nov 9, 20218
- Board memberShengda Zan Jul 26, 2016 to Dec 16, 201627
- Board memberSusan Wiviott Jul 26, 2016 to Jul 30, 201828
- Board memberThomas E. Shenk Jul 26, 2016 to Jun 30, 201729
Former names
- Kadmon Holdings, LLCAug 30, 2012 to Jul 28, 20162
Timeline
- Nov 9, 20218-K Entered a material agreement; Completed an acquisition or sale; Debt or obligation accelerated30
- Nov 5, 20218-K Shareholder vote31
- Nov 4, 20218-K Results of operations32
- Oct 28, 20218-K Other events33
- Oct 21, 20218-K Other events34
- Jul 26, 2016New chief executive Harlan Waksal becomes CEO8
Calendar
When it reported results
- Nov 4, 2021Reported quarterly or annual results32
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
30 filings to the SEC since October 2021: 1 quarterly reports, 5 major events, 11 insider forms, 1 large holders, 12 other. The latest 20:
- Feb 14, 2022SC 13G/A SCHEDULE 13G (AMENDMENT NO. 1) EDGAR
- Nov 19, 202115-12B EDGAR
- Nov 15, 2021EFFECT EDGAR
- Nov 15, 2021EFFECT EDGAR
- Nov 9, 20218-K EDGAR
- Nov 9, 2021S-8 POS EDGAR
- Nov 9, 2021S-8 POS EDGAR
- Nov 9, 2021S-8 POS EDGAR
- Nov 9, 2021S-8 POS EDGAR
- Nov 9, 2021POS AM EDGAR
- Nov 9, 2021POS AM EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
- Nov 9, 20214 OWNERSHIP DOCUMENT EDGAR
The 30 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Point72 Asset Management, L.P.SC 13G/A, 1 filing Feb 14, 202235
SEC filer profile
How Kadmon Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARKadmon Holdings, Inc.1
- CIK0001557142
- Employer ID (EIN)27-35769291
- Filer status<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- Business address450 East 29Th Street, New York, NY 100161
- Phone833-900-53661
- Shares outstanding178,521,071 as of Nov 1, 202136
- Public float$495.2M as of Jun 30, 20203
- On EDGAR sinceAug 30, 20121
- Filings443 in all: 4 (121), 8-K (100), 3 (31), SC 13G/A (23), 10-Q (17), 424B5 (17), SC 13G (17), 424B3 (16)1
All 40 form types
CORRESP (11), DEFA14A (9), UPLOAD (9), EFFECT (8), SC 13D/A (7), 10-K (5), DEF 14A (5), S-3 (4), S-8 (4), S-8 POS (4), 4/A (3), S-1/A (3), 424B4 (2), 8-A12B (2), 8-K/A (2), D (2), DRS/A (2), DRSLTR (2), POS AM (2), S-1 (2), SC 13D (2), 15-12B (1), 25 (1), 25-NSE (1), CERT (1), CERTNYS (1), CT ORDER (1), DEFM14A (1), DRS (1), FWP (1), PRE 14A (1), PREM14A (1)
- Latest filingsAnnual report (10-K) Mar 4, 2021
Quarterly report (10-Q) Nov 4, 2021
Proxy statement (DEF 14A) Apr 1, 2021
Latest 8-K (8-K) Nov 9, 2021
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARZhenping Zhu, Executive VP Biologics
- 18SEC EDGARNancy Miller-Rich, Board member
- 19SEC EDGARCynthia Schwalm, Board member
- 20SEC EDGARDavid E. Cohen, Board member
- 21SEC EDGARArthur S. Kirsch, Board member
- 22SEC EDGARSteven Meehan, Board member
- 23SEC EDGARTasos Konidaris, Board member
- 24SEC EDGARAlexandria Forbes, Board member
- 25SEC EDGARBart M. Schwartz, Board member
- 26SEC EDGARD. Dixon Boardman, Board member
- 27SEC EDGARShengda Zan, Board member
- 28SEC EDGARSusan Wiviott, Board member
- 29SEC EDGARThomas E. Shenk, Board member
- 30
- 31SEC EDGARShareholder vote
- 32SEC EDGARResults of operations
- 33SEC EDGAROther events
- 34SEC EDGAROther events
- 35
- 36